Get in Touch

This site is intended for UK healthcare professionals only and contains promotional information.UK Flag Please visit the MHRA Yellowcard site to report an Adverse Event.

Home/Therapy areas/Diabetes and Endocrinology/Diabetes and Endocrinology Webinars and HCP Resources/Primary Prevention in Primary Care: SGLT2is in Type 2 Diabetes

Primary Prevention in Primary Care: SGLT2is in Type 2 Diabetes

Invokana®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC. 

Prescribing Information can be found under Useful Resources

Primary Prevention in Primary Care: SGLT2is in Type 2 Diabetes- Dr Rajay Narain

Honorary Consultant Cardiologist, Dr Rajay Narain, talks about the disease burden of type 2 diabetes (T2D) on the NHS and the use of Invokana (canagliflozin) in the treatment of T2D. He explores the results of the CANVAS Program which looked at the effects of canagliflozin on CV, kidney and safety outcomes, and the CREDENCE Trial which was dedicated to show outcomes in T2D patients with albuminuric chronic kidney disease.

This presentation was part of The Many Faces of Diabetes national webinar on the 14th of November 2023, titled “Primary Prevention in Primary Care.

Useful Resources

Dr Rajay Narain - Honorary Consultant Cardiologist at St. George's University Hospital

Dr Rajay Narain - Honorary Consultant Cardiologist at St. George's University Hospital

Dr Narain works as a Honorary Consultant Cardiologist at St. George's University Hospital, London. He has set up the UK's first Cardio Metabolic Clinic in the NHS in London. Dr Narain is a member of the EAPCI, EAPCR, and a Council member for Stroke at the European Society of Cardiology. He is the Founder of Global Health Alliance UK, which delivers medical education at a global level . He is also Cardiology Advisor to the Govt of Ireland, Ukraine & India.

PP-IN-UK-1135 January 2024

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.

Phone 0800 085 8678

Useful Links Edit Cookies Settings
Contact Us Get in Touch

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc.

 

This website is brought to you by A. Menarini Farmaceutica Internazionale SRL, a company registered in England and Wales under No. BR016024 with its registered office at Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH.

Copyright © 2021 Menarini. All rights reserved. VAT number 143099806. PP-MN-UK-0549 May 2024